DiaMedica Valuation Multiples

DiaMedica Overview

About DiaMedica

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Founded

2000

HQ

Employees

28

Website

diamedica.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($38M)

EV

$350M

Valuation Multiples

Multiples.vc

Start free trial

DiaMedica Financials

DiaMedica reported last 12-month revenue of — and negative EBITDA of ($38M).

In the same LTM period, DiaMedica generated — in gross profit, ($38M) in EBITDA losses, and had net loss of ($35M).

DiaMedica P&L

In the most recent fiscal year, DiaMedica reported revenue of — and EBITDA of ($27M).

DiaMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX

DiaMedica Stock Performance

DiaMedica has current market cap of $405M, and enterprise value of $350M.

DiaMedica's stock price is $7.78.

DiaMedica Valuation Multiples

DiaMedica trades at (9.2x) EV/EBITDA.

DiaMedica Financial Valuation Multiples

As of March 25, 2026, DiaMedica has market cap of $405M and EV of $350M.

Equity research analysts estimate DiaMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

DiaMedica has a P/E ratio of (11.4x).

DiaMedica Margins & Growth Rates

DiaMedica's revenue in the last fiscal year grew by —.

DiaMedica's revenue per employee in the last FY averaged $0.0M.

DiaMedica Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

DiaMedica M&A Activity

DiaMedica acquired XXX companies to date.

Last acquisition by DiaMedica was on XXXXXXXX, XXXXX. DiaMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

DiaMedica Investment Activity

DiaMedica invested in XXX companies to date.

DiaMedica made its latest investment on XXXXXXXX, XXXXX. DiaMedica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).